Drotrecogin alfa (activated) (DrotAA), a recombinant human activated protein C (APC), mitigates smoke-induced elevations in pulmonary microvascular permeability and proinflammatory cytokine IL-1β levels in rats. It also inhibits coagulation and inflammation while enhancing fibrinolysis. Drotrecogin alfa (activated) is applicable in severe sepsis research [1] [2].

Drotrecogin alfa 激活剂（0-20 mg/kg，静脉注射，烟雾曝露后立即给药，单次）显著以剂量依赖性的方式减轻烟雾吸入伤害，于伤害后2小时效果明显。Drotrecogin alfa 激活剂（20 mg/kg）对肺动态顺应性呼气阶段有所改善。